The recent surge in investments into specialized pharmaceutical companies, particularly those focusing on groundbreaking therapies and complex drug development programs, has fueled what some are calling "High Investor Pharma." While the potential for blockbuster treatments and significant returns is certain, the associated risks are also notable. M